The financials
Artivion, Inc. by the numbers
Artivion, Inc. (AORT) reported revenue of $116M in Q1 2026 (quarter ended Mar 31, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 65% and net income of $1.4M (1.2% of revenue). For the full year FY2025, revenue was $441M (+14% year on year) and net income $9.8M. Its largest product in Jun 2026 was Aortic Stent Grafts at $46M, 37% of the disclosed total, ahead of On X at 24%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $116M | $99M | +18% |
| Gross profit | $75M | $64M | +19% |
| Operating income | $5.8M | $2.1M | +170% |
| Net income | $1.4M | −$505K | to a profit |
| Diluted EPS | $0.03 | −$0.01 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Aortic Stent Grafts | $46M | 37% |
| On X | $31M | 24% |
| Preservation Services | $26M | 21% |
| Surgical Sealants | $19M | 15% |
| Other Products | $3.7M | 2.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $125.8M (+8.1%)
Other Products grew +35% year on yearSurgical Sealants -0.01% year on year
Segment Latestquarter on quarteryear on year
- Aortic Stent Grafts$46.4M$46.4MQoQ +4.5%year on year +16%+4.5%+16%
- On X$30.5M$30.5MQoQ +18%year on year +19%+18%+19%
- Preservation Services$25.9M$25.9MQoQ +3.8%year on year +1.3%+3.8%+1.3%
- Surgical Sealants$19.3M$19.3MQoQ +2.6%year on year -0.01%+2.6%-0.01%
- Other Products$3.7M$3.7MQoQ +62%year on year +35%+62%+35%